TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18692823

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16495450

Group type: EXPERIMENTAL
Intervention: Memory-impaired patients with medial temporal lobe lesions
Number of subjects: 6

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 6
Study: 15566933

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg every 8 hours for </=3 doses
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg every 8 hours for </=3 doses
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sildenafil (both dosages)
Number of subjects: 14
Study: 12089976

Group type: EXPERIMENTAL
Intervention: 25% metronidazole gel
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Subgingival scaling
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combination of scaling and metronidazole gel
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (untreated quadrant)
Number of subjects: 13
Study: 9066835

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA) aqueous nasal spray (220 micrograms/day)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA) aqueous nasal spray (110 micrograms/day, dose reduction allowed)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo (during the initial 4-week study) followed by TAA aqueous (220 micrograms/day)
Number of subjects: 172
Study: 8341866

Group type: EXPERIMENTAL
Intervention: Two-sample Wilcoxon rank sum test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barthel index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monte Carlo simulation
Number of subjects: 0
Study: 3551617

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5% ophthalmic solution
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 26
Study: 31660644

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 60
Study: 29347980

Group type: EXPERIMENTAL
Intervention: Semiprone position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 0
Study: 28099665

Group type: EXPERIMENTAL
Intervention: Educational dietary intervention consisting of six counseling sessions on breastfeeding and healthy complementary feeding.
Number of subjects: 323

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 323
Study: 24314301

Group type: EXPERIMENTAL
Intervention: Audience Response System (ARS)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (verbal question-and-answer session)
Number of subjects: 63
Study: 22440071

Group type: EXPERIMENTAL
Intervention: Analytical rumination
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (writing about thoughts without emotion regulation instructions)
Number of subjects: 121
Study: 20629568

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 18

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 18
Study: 18394451

Group type: EXPERIMENTAL
Intervention: Exercise (modified Bruce protocol)
Number of subjects: 75
Study: 16651912

Group type: EXPERIMENTAL
Intervention: Forced pronation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Supination-flexion
Number of subjects: 75
Study: 14669818

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field in combination with essential oils administered for 26 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8623968

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.8 micrograms/kg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fentanyl 4.5 micrograms/kg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 33
Study: 1359666

Group type: EXPERIMENTAL
Intervention: Non-sedative antihistamine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid
Number of subjects: 35
Study: 3999380

Group type: EXPERIMENTAL
Intervention: Enflurane anesthesia
Number of subjects: 25

Group type: COMPARATOR
Intervention: Neurolept anesthesia
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Induced hypotensive anesthesia with trimetaphan
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Prone position during surgery
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Monitoring of direct arterial pressure of dorsalis pedis artery
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Core temperature monitoring
Number of subjects: 25
Study: 30126444

Group type: EXPERIMENTAL
Intervention: EMOTION intervention
Number of subjects: 602
Study: 25846070

Group type: EXPERIMENTAL
Intervention: Montelukast treatment for 9 months
Number of subjects: 2

Group type: COMPARATOR
Intervention: Routine and placebo treatment
Number of subjects: 2
Study: 25269655

Group type: EXPERIMENTAL
Intervention: Modified transtibial technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anteromedial portal technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 40
Study: 22222023

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) training (8 hours)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Basic communication skills training (control condition)
Number of subjects: 131
Study: 19531445

Group type: EXPERIMENTAL
Intervention: Accelerated treatment (omitting three cycles of FSH/IUI)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Conventional treatment (three cycles of CC/IUI, three cycles of FSH/IUI, up to six cycles of IVF)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Accelerated treatment
Number of subjects: 503
Study: 18284641

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 55

Group type: COMPARATOR
Intervention: No treatment (untreated SGA controls)
Number of subjects: 55
Study: 16084166

Group type: EXPERIMENTAL
Intervention: CABG (n = 500)
Number of subjects: 988

Group type: COMPARATOR
Intervention: PCI (n = 488)
Number of subjects: 988
Study: 11862171

Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg/d for 12 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 10550134

Group type: COMPARATOR
Intervention: 3-hour paclitaxel infusion
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: 24-hour paclitaxel infusion
Number of subjects: 563
Study: 7723466

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 2314151

Group type: EXPERIMENTAL
Intervention: Nalmefene (1 mg intravenous)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fentanyl (1 microgram/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fentanyl (1 microgram/kg) with nalmefene pretreatment
Number of subjects: 8
Study: 7401832

Group type: EXPERIMENTAL
Intervention: Topical 2% lidocaine applied to the carotid bifurcation (12 patients)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Normal saline applied to the carotid bifurcation (19 patients)
Number of subjects: 76
Study: 31693275

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous exendin (9-39) 600 pmol/kg/min
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 15
Study: 30484920

Group type: EXPERIMENTAL
Intervention: High incision (hysterotomy performed 2 cm above the plica vesicouterina)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Low incision (hysterotomy performed 2 cm below the plica vesicouterina)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both groups (high and low incision)
Number of subjects: 122
Study: 28183366

Group type: EXPERIMENTAL
Intervention: Almond-enriched high-fat lunch (A-HFL)
Number of subjects: 86

Group type: COMPARATOR
Intervention: High-carbohydrate lunch (HCL)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Almond-enriched diet (AED)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Nut-free control diet (NFD)
Number of subjects: 86
Study: 26443654

Group type: EXPERIMENTAL
Intervention: In situ simulation (ISS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Off-site simulation (OSS)
Number of subjects: 100
Study: 23598254

Group type: EXPERIMENTAL
Intervention: Static magnetic field stimulation (SMS) for 15 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study: 21270724

Group type: EXPERIMENTAL
Intervention: Psoas compartment block (PCB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Caudal block (group C)
Number of subjects: 40
Study: 19478663

Group type: EXPERIMENTAL
Intervention: Cognitive task (easy or difficult digits backward) with postural stability measured by center of pressure parameters
Number of subjects: 44
Study: 18020942

Group type: EXPERIMENTAL
Intervention: Physical Activity Counseling (PAC) intervention over 13 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Physical Activity Counseling (PAC) intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 120
Study: 15473615

Group type: EXPERIMENTAL
Intervention: Higher-dose remifentanil (0.5 microg kg(‐1)min(‐1))
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lower-dose remifentanil (0.25 microg kg(‐1)min(‐1))
Number of subjects: 75

Group type: COMPARATOR
Intervention: Alfentanil (1 microg kg(‐1)min(‐1))
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Higher-dose remifentanil
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 75
Study: 11479476

Group type: EXPERIMENTAL
Intervention: Tezosentan (5, 20, 50, and 100 mg over 1 hour each)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 9496728

Group type: EXPERIMENTAL
Intervention: F60S (steam)
Number of subjects: 8

Group type: COMPARATOR
Intervention: F60 (ETO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: F6 (ETO)
Number of subjects: 8
Study: 14688860

Group type: EXPERIMENTAL
Intervention: Rhesus‐human reassortant rotavirus (RRV‐TV) vaccine
Number of subjects: 540

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Rotavirus-related episodes of diarrhoea
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: All diarrhoeal episodes
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Rotavirus-related episodes
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Rotavirus serotype 1
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Mixed infections
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Monthly rates of rotavirus-related episodes
Number of subjects: 540
Study: 2457305

Group type: EXPERIMENTAL
Intervention: Dopexamine hydrochloride (0.5 to 2.0 micrograms/kg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dopamine (2.5 to 10 micrograms/kg/min)
Number of subjects: 12
Study: 31363748

Group type: EXPERIMENTAL
Intervention: Combined household-level piped water and sanitation intervention
Number of subjects: 2398

Group type: COMPARATOR
Intervention: Control villages
Number of subjects: 2398
Study: 27497519

Group type: EXPERIMENTAL
Intervention: Salmon intake (two 150-g portions per week)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (habitual diet low in oily fish)
Number of subjects: 123
Study: 25998481

Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide (IDegLira)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin degludec (IDeg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 0
Study: 23790990

Group type: EXPERIMENTAL
Intervention: Participatory parent-focused approach in preschools
Number of subjects: 826

Group type: COMPARATOR
Intervention: State-sponsored program with twice-weekly gym classes
Number of subjects: 826
Study: 21627396

Group type: EXPERIMENTAL
Intervention: PIVC with blood control (BD Insyte Autoguard * BC Shielded IV Catheter)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Conventional PIVC (BD Insyte Autoguard Shielded IV Catheter)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: PIVC-BC with venous compression
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: PIVC-BC without venous compression
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: PIVC with blood control (PIVC-BC)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Conventional PIVC
Number of subjects: 234
Study: 19466288

Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CSA)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Combined spinal epidural anesthesia (CSE)
Number of subjects: 240
Study: 16304673

Group type: EXPERIMENTAL
Intervention: Desmopressin treatment
Number of subjects: 632
Study: 15450647

Group type: EXPERIMENTAL
Intervention: Combined counseling and case management behavioral intervention using motivational interviewing strategies
Number of subjects: 440

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Combined counseling and case management behavioral intervention
Number of subjects: 440
Study: 11355917

Group type: EXPERIMENTAL
Intervention: Screening using faecal occult blood tests, endoscopic methods, and different tumour markers; specific dosages and durations not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary prevention by dietary intervention and drugs; specific details not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different screening methods in populations with varying risk of colorectal cancer; specific methods not detailed.
Number of subjects: 0
Study: 9746023

Group type: EXPERIMENTAL
Intervention: Witnessed resuscitation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not allowed to witness resuscitation)
Number of subjects: 25
Study: 11548229

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Hyalgan, Fidia SpA, Italy)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 12
Study: 3061425

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (mean dose 11.5 mg over 3.4 min)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (mean dose 6.0 mg over 3.3 min)
Number of subjects: 102
Study: 30425347

Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 21 (FGF-21) levels within the highest tertile
Number of subjects: 626
Study: 27533263

Group type: EXPERIMENTAL
Intervention: Audiovisual orientation concerning the patients' conditions
Number of subjects: 210

Group type: COMPARATOR
Intervention: Routine orientation of the unit
Number of subjects: 210
Study: 25605544

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human erythropoietin (rhEPO) 33,000 IU administered at days 1-3
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone 1,000 mg per day for 3 days + 0.9% normal saline (placebo)
Number of subjects: 30
Study: 23128366

Group type: EXPERIMENTAL
Intervention: Web communication
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Print communication
Number of subjects: 904

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 904
Study: 21168115

Group type: EXPERIMENTAL
Intervention: Lavender oil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Povidone-iodine
Number of subjects: 120
Study: 18685477

Group type: EXPERIMENTAL
Intervention: Conflict resolution training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12452944

Group type: EXPERIMENTAL
Intervention: High-dose interferon-alpha therapy (daily 9 MU for 4 weeks, then 6 MU for weeks 5-8, 3 MU for weeks 9-12, and 1.5 MU for weeks 13-48) with ribavirin (1000-1200 mg) and amantadine (200 mg) daily for 48 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard-dosage interferon-alpha therapy (thrice weekly 6 MU for 12 weeks, then 3 MU for 36 weeks) with ribavirin (1000-1200 mg) and amantadine (200 mg) daily for 48 weeks
Number of subjects: 30
Study: 9605002

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg intravenously, 5 minutes before chemotherapy)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg intravenously, 5 minutes before chemotherapy) with additional doses if vomiting occurs
Number of subjects: 50
Study: 8583516

Group type: EXPERIMENTAL
Intervention: Enhanced Care day treatment program including drug free contingent work therapy and housing
Number of subjects: 131

Group type: COMPARATOR
Intervention: Usual Care outpatient program
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: All subjects across four evaluation points
Number of subjects: 131
Study: 2666339

Group type: EXPERIMENTAL
Intervention: RHEZ6 regimen (4 drug, 6 months: Rifampicin, Isoniazid, Ethambutol, Pyrazinamide)
Number of subjects: 288

Group type: COMPARATOR
Intervention: RHE9 regimen (3 drug, 9 months: Rifampicin, Isoniazid, Ethambutol)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: RHEZ6 regimen
Number of subjects: 288
Study: 140084

Group type: EXPERIMENTAL
Intervention: bufexamac cream
Number of subjects: 193

Group type: COMPARATOR
Intervention: 0.1% triamcinolone acetonide cream
Number of subjects: 193

Group type: COMPARATOR
Intervention: 1% hydrocortisone cream
Number of subjects: 193

Group type: COMPARATOR
Intervention: placebo cream
Number of subjects: 193
Study: 28869478

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baduanjin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 25654175

Group type: EXPERIMENTAL
Intervention: Passive quality improvement interventions (education, generic protocol, order set, local champions)
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Active quality improvement interventions (nurse specialist, monthly audit-feedback, network educational events, internet blog)
Number of subjects: 934

Group type: COMPARATOR
Intervention: Baseline standard of care (no intervention)
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Overall survival to hospital discharge
Number of subjects: 934
Study: 24354113

Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate
Number of subjects: 107

Group type: COMPARATOR
Intervention: Leuprolide acetate
Number of subjects: 107
Study: 22480093

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg thrice daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg thrice daily
Number of subjects: 80
Study: 19523083

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test in obese children and adolescents
Number of subjects: 1534
Study: 16733916

Group type: EXPERIMENTAL
Intervention: estradiol valerate (E2 V) 1 mg/d + medroxyprogesterone acetate (MPA) 2 mg/d
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: conjugated equine estrogen 0.45 mg/d + MPA 2 mg/d
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: tibolone 1.25 mg/d
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Chinese formulated herbs product (Kuntai) 4# tid
Number of subjects: 136
Study: 14985216

Group type: EXPERIMENTAL
Intervention: Phytic acid (1.49 mmol) added to test meal
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Phytic acid (0.75 mmol) added to test meal
Number of subjects: 9

Group type: COMPARATOR
Intervention: No added phytic acid
Number of subjects: 9
Study: 11307804

Group type: EXPERIMENTAL
Intervention: AR-C69931MX at 2 microg/kg/min for 21 h (Part 1)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: AR-C69931MX at up to 69 h (Part 2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: AR-C69931MX at 4 microg/kg/min for up to 69 h (Part 3)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: AR-C69931MX (all parts)
Number of subjects: 39
Study: 9150774

Group type: EXPERIMENTAL
Intervention: Adenosine infusion, 80 micrograms.kg-1.min-1 during surgery and 40 micrograms.kg-1.min-1 for 3 hours postoperatively
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo infusion during surgery
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Adenosine infusion
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 43
Study: 7962388

Group type: EXPERIMENTAL
Intervention: Vero cell co-culture system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vero cell monolayer for 24 hours
Number of subjects: 0
Study: 29543076

Group type: EXPERIMENTAL
Intervention: 3° × 180° COD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Collision workloads
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total distance per minute
Number of subjects: 0
Study: 29889390

Group type: EXPERIMENTAL
Intervention: Monotherapy with proton pump inhibitors (PPIs)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Combination therapy with PPI + ursodeoxycholic acid (UDCA)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (normal body weight)
Number of subjects: 131
Study: 24867408

Group type: COMPARATOR
Intervention: 0 g bLF daily for 1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.5 g bLF daily for 1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3.0 g bLF daily for 1 year
Number of subjects: 0
Study: 22302533

Group type: EXPERIMENTAL
Intervention: Laparoscopic ischemic conditioning (LIC) prior to MIE
Number of subjects: 16

Group type: COMPARATOR
Intervention: MIE without laparoscopic ischemic conditioning (N)
Number of subjects: 16
Study: 20138189

Group type: EXPERIMENTAL
Intervention: GM-CSF (150 microg) + hepatitis B vaccine (20 microg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (40 microg) only
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hepatitis B vaccine (20 microg) each time
Number of subjects: 100
Study: 19457618

Group type: EXPERIMENTAL
Intervention: Oxytocin (single dose administered intranasally)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (single dose administered intranasally)
Number of subjects: 26
Study: 16794364

Group type: EXPERIMENTAL
Intervention: lanreotide 30 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 14631473

Group type: EXPERIMENTAL
Intervention: Increased BMI
Number of subjects: 5886

Group type: EXPERIMENTAL
Intervention: Increased waist circumference
Number of subjects: 5886

Group type: EXPERIMENTAL
Intervention: Increased waist-to-hip ratio
Number of subjects: 5886